Patients with PD-1 blockade-resistant TNBC have elevated levels of oncogenic LINK-A, which facilitates the K48-polyubiquitination-mediated degradation of the antigen peptide-loading complex (PLC) and intrinsic tumor suppressors Rb and p53, leading to reduced antigen presentation and tumor-specific immune response [158]. The gene discussed is TP53; the disease is neoplasm.